How INFORM-1 May Change HCV Drug Development

Morrison, Trista
May 2009
BioWorld Financial Watch;5/4/2009, Vol. 17 Issue 18, p1
The article discusses preliminary data on INFORM-1, the first study to combine two direct-acting antivirals for hepatitis C, which was presented at the 44th annual meeting of the European Association for the Study of the Liver (EASL). The encouraging outcomes of the trial are identified, such as how antiviral cocktails may revolutionize hepatitis C virus (HCV) treatment. INFORM-1 combined the protease inhibitor R7227 with the polymerase inhibitor R7128.


Related Articles

  • Fragment-Based Development of HCV Protease Inhibitors for the Treatment of Hepatitis C. Karelson, Mati; Dobchev, Dimitar A.; Karelson, Gunnar; Tamm, Tarmo; Tämm, Kaido; Nikonov, Andrei; Mutso, Margit; Merits, Andres // Current Computer-Aided Drug Design;Mar2012, Vol. 8 Issue 1, p55 

    A novel computational technology based on fragmentation of the chemical compounds has been used for the fast and efficient prediction of activities of prospective protease inhibitors of the hepatitis C virus. This study spans over a discovery cycle from the theoretical prediction of new HCV NS3...

  • HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Kazuaki Chayama; Hayes, C. Nelson // Viruses (1999-4915);2015, Vol. 7 Issue 10, p5328 

    Sustained virological response (SVR) rates have increased dramatically following the approval of direct acting antiviral (DAA) therapies. While individual DAAs have a low barrier to resistance, most patients can be successfully treated using DAA combination therapy. However, DAAs are vulnerable...

  • P1 and P1; Optimization of [3,4]-Bicycloproline P2 Incorporated Tetrapeptidyl α-Ketoamide Based HCV Protease Inhibitors. Shu-Hui Chen; Lamar, Jason; Yip, Yvonne; Victor, Frantz; Johnson, Robert B.; Wang, Q. May; Glass, John I.; Heinz, Beverly; Colacino, Joseph; Deqi Guo; Tebbe, Mark; Munroe, John E. // Letters in Drug Design & Discovery;Mar2005, Vol. 2 Issue 2, p118 

    We describe herein tetrapeptidyl α-ketoamide 4A based systematic P1 modifications alone or/and in combination with further P1; variations. These SAR efforts led to the discovery of a number of potent and selective HCV NS3 protease inhibitors such as 4B, 9, and 12 endowed with impressive...

  • Allosteric Inhibitors of Hepatitis C NS5B RNA-dependent RNA Polymerase°. Condon, Stephen M.; LaPorte, Matthew G.; Herbertz, Torsten // Current Medicinal Chemistry - Anti-Infective Agents;Apr2005, Vol. 4 Issue 2, p99 

    Infection with HCV is a global concern. Estimates from the WHO suggest that over 170 million people are infected worldwide with over 2.7 million people infected in the US. Current therapies including interferon (IFN-α) and ribavirin are ineffective against many HCV genotypes and a sustained...

  • The changing therapeutic landscape for hepatitis C. Dore, Gregory J. // Medical Journal of Australia;6/4/2012, Vol. 196 Issue 10, p629 

    The article discusses developments in the treatment of hepatitis C virus (HCV) infection in Australia. Recent developments in direct-acting antiviral (DAA) therapy are reported. The challenges of the initial clinical use of HCV protease inhibitors are identified. Recommendations for using DAA...

  • Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials. Chary, Aarthi; Holodniy, Mark // Reviews on Recent Clinical Trials;Sep2010, Vol. 5 Issue 3, p158 

    Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma. Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with...

  • Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. Wyles, David L. // Journal of Infectious Diseases;Mar2013, Vol. 207 Issue suppl_1, pS33 

    The addition of hepatitis C virus (HCV) protease inhibitors (PIs) to interferon and ribavirin therapy has significantly improved the efficacy of treatment for HCV infection. However, for patients who do not respond to therapy, the selection of HCV variants with resistance to PIs is likely....

  • Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease. Wang, Huiqun; Geng, Lingling; Chen, Bo-Zhen; Ji, Mingjuan // Biochemistry & Cell Biology;2014, Vol. 92 Issue 5, p357 

    Narlaprevir is a novel NS3/4A protease inhibitor of hepatitis C virus (HCV), and it has been tested in a phase II clinical trial recently. However, distinct drug-resistance of Narlaprevir has been discovered. In our study, the molecular mechanisms of drug-resistance of Narlaprevir due to the...

  • A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection. Adiwijaya, Bambang S.; Kieffer, Tara L.; Henshaw, Joshua; Eisenhauer, Karen; Kimko, Holly; Alam, John J.; Kauffman, Robert S.; Garg, Varun // PLoS Computational Biology;Jan2012, Vol. 8 Issue 1, p1 

    We propose an integrative, mechanistic model that integrates in vitro virology data, pharmacokinetics, and viral response to a combination regimen of a direct-acting antiviral (telaprevir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ ribavirin (PR) in patients with genotype 1...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics